Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Diabetes Mellitus Type 2; Obesity, Morbid

Study type: Observational

Funder types: Industry

Identifiers

NCT00957957

0000-134

2009_002 (Other Identifier)

Details and patient eligibility

About

This study will examine changes in various gut-derived hormones in obese type 2 diabetic patients before and after elective bariatric surgery.

Enrollment: 22 patients

Sex: All

Ages: 20 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented type 2 diabetes with total disease duration ≤10 years
• BMI of at least 35 kg/m^2
• Patient is a surgical candidate for either RYGBP, GBS or vertical sleeve gastrectomy (VSG)

Exclusion criteria

• Any illness that might confound the results of the study or pose additional risk to the patient by participation
• History of stroke, seizures, or other major neurological disorder
• History of cancer
• Patient uses or has used any medication that can alter body weight
• Patient is unwilling or unable to follow study procedures

Trial design

22 participants in 2 patient groups

1

Description:

Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)

2

Description:

Participants having elective gastric banding surgery (GB)